Gut Microbiota Rewrites Your Epigenome to Drive or Prevent Intestinal Disease
A landmark 2025 review maps how gut bacteria alter DNA methylation, histone marks, and RNA modifications to drive IBD and colorectal cancer.
Summary
This comprehensive 2025 review in Gut Microbes examines how gut microbiota drive intestinal disease through epigenetic reprogramming. The authors detail how microbial metabolites and dysbiosis alter DNA methylation, histone modifications, non-coding RNAs, and m6A RNA methylation to activate inflammatory pathways and cancer-promoting genes linked to IBD and colorectal cancer. Environmental triggers including diet, smoking, alcohol, and air pollution compound these microbial epigenetic effects. The review also evaluates emerging therapeutic strategies—probiotics, prebiotics, postbiotics, fecal microbiota transplantation, dietary modification, and phage therapy—that may reverse pathological epigenetic patterns. The authors conclude that targeting microbiome-epigenome interactions represents a promising frontier for personalized intestinal disease treatment.
Detailed Summary
Intestinal diseases including inflammatory bowel disease (IBD) and colorectal cancer (CRC) affect millions worldwide and remain therapeutically challenging due to their multifactorial origins. Although gut microbiota dysbiosis is known to contribute to these diseases, the precise epigenetic mechanisms connecting microbial imbalance to pathological gene expression have lacked systematic synthesis—until now. This 2025 review in Gut Microbes by Zhang, Liu, Li, and colleagues fills that gap with a thorough mechanistic framework.
The review explains that gut bacteria function as epigenetic regulators by producing metabolites that serve as substrates or cofactors for chromatin-modifying enzymes. Short-chain fatty acids (SCFAs) like butyrate act as histone deacetylase inhibitors, promoting anti-inflammatory gene expression. Conversely, dysbiosis reduces SCFA production, shifting the epigenetic landscape toward pro-inflammatory states. Microbially influenced one-carbon metabolism affects S-adenosylmethionine availability, directly impacting DNA methylation patterns at cancer-relevant loci such as SEPT9, VMP1, ITGB2, and TXK.
Four major epigenetic mechanisms are addressed in detail. DNA methylation changes—both hypermethylation of tumor suppressor genes and hypomethylation of oncogenes—are linked to specific microbiome shifts in CRC patients. Histone modifications including acetylation, methylation, lactylation, and crotonylation are shaped by bacterial metabolites and alter chromatin accessibility at immune-regulatory promoters relevant to IBD. Non-coding RNAs, particularly miRNAs and lncRNAs, are dysregulated by microbial signals and modulate post-transcriptional silencing of key inflammatory and apoptotic genes. Finally, N6-methyladenosine (m6A) mRNA modification—the most abundant eukaryotic mRNA modification—is emerging as a gut microbiota-responsive layer that controls RNA stability and translation of immune mediators.
Environmental co-factors including diet, smoking, alcohol, and air pollution intersect with microbial epigenetic programming, amplifying or sometimes mitigating disease risk. Animal models and human cell studies cited throughout the review demonstrate that these interactions activate NF-κB, Wnt/β-catenin, and TGF-β signaling pathways, connecting microbiome-epigenome crosstalk directly to IBD flares and CRC progression.
Therapeutically, the review highlights microbiome-targeted interventions designed to restore normal epigenetic patterns. Probiotics and prebiotics can re-establish SCFA production and normalize histone acetylation. Postbiotics deliver bioactive microbial products directly. Fecal microbiota transplantation (FMT) has shown promise in rebalancing both microbial composition and downstream epigenetic marks. Phage therapy offers precision targeting of pathogenic strains driving epigenetic dysregulation. The authors emphasize that integrating epigenetic biomarkers with microbiome profiling could enable more personalized and earlier diagnosis and treatment strategies for both IBD and CRC.
Key Findings
- Gut microbiota dysbiosis drives IBD and CRC partly by altering host DNA methylation at tumor suppressor and immune-regulatory gene loci.
- SCFAs like butyrate act as histone deacetylase inhibitors; dysbiosis reduces SCFAs and shifts chromatin toward pro-inflammatory states.
- m6A RNA methylation is newly identified as a microbiota-responsive epigenetic layer controlling immune mediator expression in intestinal disease.
- FMT, probiotics, and phage therapy may reverse pathological epigenetic patterns by restoring healthy microbial communities.
- Environmental factors—diet, smoking, alcohol, air pollution—compound microbial epigenetic effects on IBD and CRC risk.
Methodology
This is a narrative review synthesizing mechanistic studies from animal models (including germ-free mice) and human cell systems alongside clinical and epidemiological data. The authors integrated findings across four epigenetic layers—DNA methylation, histone modifications, non-coding RNAs, and m6A—drawing on approximately 290 references published up to early 2025.
Study Limitations
As a review, the paper does not generate primary data, and causal directionality between specific microbial taxa and particular epigenetic changes often remains correlative. Many mechanistic findings are from animal or in vitro models, limiting direct clinical translation. The field lacks large-scale human epigenome-wide association studies stratified by microbiome composition.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: